Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftolozane/tazobactam - Cubist Pharmaceuticals

Drug Profile

Ceftolozane/tazobactam - Cubist Pharmaceuticals

Alternative Names: CXA-101/tazobactam; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Cubist Pharmaceuticals; M. D. Anderson Cancer Center; Merck Sharp & Dohme
  • Class 2 ring heterocyclic compounds; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Urinary tract infections
  • Registered Pyelonephritis
  • Phase III Nosocomial pneumonia
  • Phase II Bacterial infections

Most Recent Events

  • 11 Sep 2018 Merck & Co. plans to submit sNDA for Nosocomial pneumonia in USA and European Union
  • 24 Jun 2018 Biomarkers information updated
  • 06 Jun 2018 Cubist Pharmaceuticals completes a phase III trial in Nosocomial pneumonia in Croatia, Portugal, Greece, Germany, USA, the United Kingdom, Austria, Estonia, Belgium, Latvia, Czech Republic, Hungary and Slovakia (IV) (EudraCT2012-002862-11) (NCT02070757)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top